Literature DB >> 1531244

Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes.

S M Haffner1, K R Tuttle, D L Rainwater.   

Abstract

Recently, lipoprotein (a) [Lp(a)] has been identified as a major risk factor for coronary heart disease. No data are available on the effect of improved metabolic control on plasma Lp(a) concentrations in subjects with type II diabetes mellitus, a group at high risk for coronary heart disease. We examined the effects of improved metabolic control on plasma lipid and lipoproteins and Lp(a) concentrations in 12 subjects before and after 21 days of tight metabolic control. Glycosylated hemoglobin declined from 8.9% to 6.9% (P less than .002). Lp(a) increased slightly from 21.4 to 25.8 mg/dL (P = .119) with improved metabolic control. There were no significant differences in total, low-density, or high-density cholesterol values, although the decline in triglyceride concentrations was statistically significant. The distribution of apolipoprotein (a) [apo (a)] isoforms in subjects with type II diabetes mellitus was not unusual and the apo (a) isoform patterns did not change with improved metabolic control. Although the number of subjects was small, there was no decline in Lp(a) concentrations with improved control and thus the effect of glycemic control on Lp(a) concentrations may be much smaller in type II than in type I diabetes. These results suggest that diabetic subjects with elevated Lp(a) concentrations should have intensive management of conventional cardiovascular risk factors such as high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), and blood pressure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531244     DOI: 10.1016/0026-0495(92)90136-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

Authors:  G Jerums; T J Allen; C Tsalamandris; A Akdeniz; A Sinha; R Gilbert; M E Cooper
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

2.  Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control.

Authors:  Seema Singla; Kiranjeet Kaur; Gurdeep Kaur; Habir Kaur; Jasbinder Kaur; Shivani Jaswal
Journal:  Int J Diabetes Dev Ctries       Date:  2009-04

Review 3.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

4.  Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Santamaria; J D Best
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

5.  Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.

Authors:  A Császár; H Dieplinger; C Sandholzer; I Karádi; E Juhász; H Drexel; T Halmos; L Romics; J R Patsch; G Utermann
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

6.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

7.  Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I.

Authors:  P D Zenobi; P Holzmann; Y Glatz; W F Riesen; E R Froesch
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

Review 8.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

Review 9.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

10.  Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus.

Authors:  Alfred Azenabor; Anthonia O Ogbera; Ngozi E Adejumo; Adejimi O Adejare
Journal:  J Res Med Sci       Date:  2011-10       Impact factor: 1.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.